Brilacidin

Generic Name
Brilacidin
Brand Names
-
Drug Type
Small Molecule
Chemical Formula
C40H50F6N14O6
CAS Number
1224095-98-0
Unique Ingredient Identifier
I1679X069H
Background

Brilacidin is under investigation for the supportive care of Mucositis, Stomatitis, Mouth Diseases, and Head and Neck Neoplasms.

Associated Conditions
-
Associated Therapies
-

A Study to Evaluate the Efficacy and Safety of Brilacidin in Hospitalized Participants With COVID-19

First Posted Date
2021-03-05
Last Posted Date
2022-09-16
Lead Sponsor
Innovation Pharmaceuticals, Inc.
Target Recruit Count
120
Registration Number
NCT04784897
Locations
🇷🇺

IPI Investigator Site, Saint Petersburg, Russian Federation

A Study to Investigate the Use of Delayed Release Tablets for Colonic Delivery of Brilacidin in Healthy Volunteers

First Posted Date
2020-01-27
Last Posted Date
2020-02-24
Lead Sponsor
Innovation Pharmaceuticals, Inc.
Target Recruit Count
9
Registration Number
NCT04240223
Locations
🇬🇧

BDD Pharma Ltd, Glasgow, Scotland, United Kingdom

Study of the Effects of Brilacidin Oral Rinse on Radiation-induced Oral Mucositis in Patients With Head and Neck Cancer

First Posted Date
2014-12-24
Last Posted Date
2019-01-16
Lead Sponsor
Innovation Pharmaceuticals, Inc.
Target Recruit Count
61
Registration Number
NCT02324335

Efficacy and Safety Study of Brilacidin to Treat Serious Skin Infections

First Posted Date
2014-02-03
Last Posted Date
2018-09-26
Lead Sponsor
Cellceutix Corporation
Target Recruit Count
215
Registration Number
NCT02052388
Locations
🇺🇸

eStudy Site, Las Vegas, Nevada, United States

© Copyright 2024. All Rights Reserved by MedPath